AR077481A1 - Derivados de imidazol - Google Patents
Derivados de imidazolInfo
- Publication number
- AR077481A1 AR077481A1 ARP100102580A ARP100102580A AR077481A1 AR 077481 A1 AR077481 A1 AR 077481A1 AR P100102580 A ARP100102580 A AR P100102580A AR P100102580 A ARP100102580 A AR P100102580A AR 077481 A1 AR077481 A1 AR 077481A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- independently
- alkoxyalkyl
- hydrogen
- hydroxyalkyl
- Prior art date
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 abstract 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Los compuestos de la formula general (1), son antagonistas de los receptores metabotropicos de glutamato. Estos pueden utilizarse en el tratamiento o la prevencion de trastornos mediatizados por el receptor mGIuR5. Reivindicacion 1: Un compuesto de la formula general (1) en donde R1, significa halogeno, alquilo inferior o alcoxi inferior; R2, significa alquilo inferior, hidroxialquilo inferior, o alcoxialquilo inferior; R3, significa hidrogeno, alquilo inferior, hidroxialquilo inferior o alcoxialquilo; Q, significa o -N= o -CH=; R4, es un grupo de la formula (2a) o (2b) en donde, X, Y y Z, son, de una forma independiente, -CH= o -N=; y en donde, solamente una de entre las X o Y, puede ser un átomo de nitrogeno; R5 y R6 son, de una forma independiente, hidrogeno, alquilo inferior, hidroxialquilo inferior, alcoxialquilo inferior, -(CH2)m-(CO)O-alquilo inferior, -(CH2)m-S(O)2-alquilo inferior, -(CH2)m-C(O)-NR'R'', y en donde, m 0-3 y R' y Rö son, de una forma independiente, hidrogeno o alquilo inferior, así como las sales farmacéuticamente aceptables de éstos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09165780 | 2009-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR077481A1 true AR077481A1 (es) | 2011-08-31 |
Family
ID=42358156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100102580A AR077481A1 (es) | 2009-07-17 | 2010-07-15 | Derivados de imidazol |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US8334287B2 (es) |
| EP (1) | EP2456765B1 (es) |
| JP (1) | JP5667182B2 (es) |
| KR (1) | KR101431347B1 (es) |
| CN (1) | CN102471309B (es) |
| AR (1) | AR077481A1 (es) |
| AU (1) | AU2010272585B2 (es) |
| BR (1) | BR112012001092A2 (es) |
| CA (1) | CA2765921C (es) |
| CL (1) | CL2012000102A1 (es) |
| CO (1) | CO6400142A2 (es) |
| CR (1) | CR20110659A (es) |
| CY (1) | CY1114186T1 (es) |
| DK (1) | DK2456765T3 (es) |
| EC (1) | ECSP12011611A (es) |
| ES (1) | ES2411467T3 (es) |
| HR (1) | HRP20130657T1 (es) |
| IL (1) | IL216746A (es) |
| MA (1) | MA33386B1 (es) |
| MX (1) | MX2012000814A (es) |
| MY (1) | MY156878A (es) |
| NZ (1) | NZ596810A (es) |
| PE (1) | PE20120397A1 (es) |
| PL (1) | PL2456765T3 (es) |
| PT (1) | PT2456765E (es) |
| RS (1) | RS52901B (es) |
| RU (1) | RU2527106C2 (es) |
| SG (1) | SG178052A1 (es) |
| SI (1) | SI2456765T1 (es) |
| TW (1) | TWI423964B (es) |
| UA (1) | UA107086C2 (es) |
| WO (1) | WO2011006910A1 (es) |
| ZA (1) | ZA201109451B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA113223C2 (xx) * | 2012-08-13 | 2016-12-26 | Арилетинілпіримідини | |
| WO2015143164A1 (en) * | 2014-03-19 | 2015-09-24 | President And Fellows Of Harvard College | Antimicrobial agents and screening methods |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1028954E (pt) * | 1997-04-24 | 2003-11-28 | Ortho Mcneil Pharm Inc | Imidazoles substituidos uteis no tratamento de doencas inflamatorias |
| KR100515549B1 (ko) | 2000-12-04 | 2005-09-20 | 에프. 호프만-라 로슈 아게 | 글루타메이트 수용체 길항제로서의 페닐에테닐 또는페닐에티닐 유도체 |
| GB0128996D0 (en) | 2001-12-04 | 2002-01-23 | Novartis Ag | Organic compounds |
| TWI292318B (en) * | 2003-03-10 | 2008-01-11 | Hoffmann La Roche | Imidazol-4-yl-ethynyl-pyridine derivatives |
| UA80888C2 (en) * | 2003-06-05 | 2007-11-12 | Hoffmann La Roche | Imidazole derivatives as glutmate receptor antagonists |
| AU2004247368B2 (en) * | 2003-06-12 | 2007-11-22 | F. Hoffmann-La Roche Ag | Heteroaryl-substituted imidazole derivatives as glutamate receptor antagonists |
| US7452909B2 (en) | 2003-09-04 | 2008-11-18 | Hoffman-La Roche Inc. | Imidazole derivatives |
| AU2005250101B2 (en) * | 2004-06-01 | 2011-08-25 | F. Hoffmann-La Roche Ag | Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mGlu5 receptor antagonists |
| KR100907108B1 (ko) * | 2004-06-01 | 2009-07-09 | 에프. 호프만-라 로슈 아게 | Ｍｇｌｕ5 수용체 길항제로서 피리딘-4-일-에틴일-이미다졸및 피라졸 |
| JP2010510314A (ja) | 2006-11-22 | 2010-04-02 | シーサイド セラピューティクス，エルエルシー | 精神遅滞、ダウン症候群、脆弱ｘ症候群および自閉症の治療方法 |
-
2010
- 2010-07-09 US US12/833,017 patent/US8334287B2/en active Active
- 2010-07-14 WO PCT/EP2010/060097 patent/WO2011006910A1/en not_active Ceased
- 2010-07-14 CA CA2765921A patent/CA2765921C/en not_active Expired - Fee Related
- 2010-07-14 UA UAA201201027A patent/UA107086C2/ru unknown
- 2010-07-14 PT PT107301921T patent/PT2456765E/pt unknown
- 2010-07-14 HR HRP20130657AT patent/HRP20130657T1/hr unknown
- 2010-07-14 MX MX2012000814A patent/MX2012000814A/es active IP Right Grant
- 2010-07-14 TW TW099123206A patent/TWI423964B/zh not_active IP Right Cessation
- 2010-07-14 JP JP2012520013A patent/JP5667182B2/ja active Active
- 2010-07-14 SI SI201030209T patent/SI2456765T1/sl unknown
- 2010-07-14 EP EP10730192.1A patent/EP2456765B1/en active Active
- 2010-07-14 KR KR1020127004121A patent/KR101431347B1/ko not_active Expired - Fee Related
- 2010-07-14 PE PE2012000035A patent/PE20120397A1/es not_active Application Discontinuation
- 2010-07-14 ES ES10730192T patent/ES2411467T3/es active Active
- 2010-07-14 PL PL10730192T patent/PL2456765T3/pl unknown
- 2010-07-14 RS RS20130331A patent/RS52901B/sr unknown
- 2010-07-14 MY MYPI2012000151A patent/MY156878A/en unknown
- 2010-07-14 AU AU2010272585A patent/AU2010272585B2/en not_active Ceased
- 2010-07-14 BR BR112012001092-1A patent/BR112012001092A2/pt not_active Application Discontinuation
- 2010-07-14 RU RU2012104399/04A patent/RU2527106C2/ru not_active IP Right Cessation
- 2010-07-14 DK DK10730192.1T patent/DK2456765T3/da active
- 2010-07-14 CN CN201080031886.6A patent/CN102471309B/zh active Active
- 2010-07-14 MA MA34494A patent/MA33386B1/fr unknown
- 2010-07-14 NZ NZ596810A patent/NZ596810A/en not_active IP Right Cessation
- 2010-07-14 SG SG2012003661A patent/SG178052A1/en unknown
- 2010-07-15 AR ARP100102580A patent/AR077481A1/es unknown
-
2011
- 2011-11-29 CO CO11164352A patent/CO6400142A2/es active IP Right Grant
- 2011-12-01 IL IL216746A patent/IL216746A/en not_active IP Right Cessation
- 2011-12-08 CR CR20110659A patent/CR20110659A/es unknown
- 2011-12-21 ZA ZA2011/09451A patent/ZA201109451B/en unknown
-
2012
- 2012-01-13 CL CL2012000102A patent/CL2012000102A1/es unknown
- 2012-01-17 EC EC2012011611A patent/ECSP12011611A/es unknown
-
2013
- 2013-07-22 CY CY20131100614T patent/CY1114186T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20221264A1 (es) | Inhibidores de egfr | |
| ECSP034640A (es) | Derivados de feniletenilo o feniletinilo como antagonistas del receptor del glutamato | |
| CO6140030A2 (es) | Derivados de 4-bencilftalazinona 2-sustituidos como antagonistas de histamina h1 y h3 | |
| CY1112601T1 (el) | Υποκατεστημενα παραγωγα 1-πιπεριδιν-4-υλ-4-πυρρολιδιν-3-υλ-πιπεραζινης και χρηση αυτων ως ανταγωνιστων νευροκινινης | |
| DK2152709T3 (da) | Morphinanforbindelser | |
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| MY194461A (en) | N-[2-(1-benzylpiperidin-4-yl)4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases | |
| PE20170774A1 (es) | Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos | |
| PE20081665A1 (es) | Antagonistas del receptor de dopamina 2 de rapida disociacion | |
| NO20060774L (no) | Kinolin- og kinazolinderivater som har affinitet for 5HT1-typereseptorer | |
| AR040278A1 (es) | Ligandos del receptor de glucocorticoides para el tratamiento de trastornos metabolicos | |
| NO20071108L (no) | Nye 4-benzylidenpiperidinderivater | |
| AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
| AR049696A1 (es) | Derivados de indol | |
| MX390264B (es) | Antagonistas d2, metodos de sintesis y metodos de uso. | |
| PE20141598A1 (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| EA201270421A1 (ru) | 1,2-дигидро-2-оксохинолиновые соединения в качестве лигандов рецептора 5-нт | |
| EP1617806A4 (en) | SELECTIVE SPIROCYCLIC GLUCOCORTICOID RECEPTOR MODULATORS | |
| PE20060457A1 (es) | Derivados de difenil eter como antagonistas de los receptores 5ht2 | |
| AR077481A1 (es) | Derivados de imidazol | |
| PH12015502692B1 (en) | Ethynyl derivatives as metabotropic glutamate receptor antagonists | |
| DE602005021150D1 (de) | 3-substituierte pyridinderivate als h3-antagonisten | |
| AR068381A1 (es) | Compuestos de quinolina apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6 | |
| ECSP066853A (es) | Nuevos derivados de bencil (ideno) -lactamas | |
| PE20060632A1 (es) | Derivados de arilsulfonilestilbeno como antagonistas de los receptores 5-ht2a |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |